共 50 条
- [21] Design, synthesis, anti-tumor activity and mechanism of novel PROTACs as degraders of PD-L1 and inhibitors of PD-1/PD-L1 interactionBIOORGANIC & MEDICINAL CHEMISTRY, 2024, 111Zhang, FengYu, QimengWu, CaiyunSun, ShishiWang, YuWang, RuiChen, ZejieZhang, HuaXiong, XuqiongAwadasseid, AnnoorRao, GuowuZhao, XiaoyinZhang, Wen
- [22] Reversing tumor immunosuppressive microenvironment via targeting codelivery of CpG ODNs/PD-L1 peptide antagonists to enhance the immune checkpoint blockade-based anti-tumor effectEUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 168Zhang, MinFang, ZhouZhang, HaitaoCui, MingxiaoWang, MingfuLiu, Kehai
- [23] Dual targeting autoinflammation and PD-L1/L2 immune checkpoint by EGCG augments anti-tumor effects in melanomaJOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (05) : S145 - S145Li, Y.Menon, D. RavindranMathew, D.Torres, R.Fujita, M.
- [24] Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironmentCancer Immunology, Immunotherapy, 2019, 68 : 201 - 211Daisuke UmezuNana OkadaYukimi SakodaKeishi AdachiToshiyasu OjimaHiroki YamaueMasatoshi EtoKoji Tamada
- [25] Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironmentCANCER IMMUNOLOGY IMMUNOTHERAPY, 2019, 68 (02) : 201 - 211Umezu, DaisukeOkada, NanaSakoda, YukimiAdachi, KeishiOjima, ToshiyasuYamaue, HirokiEto, MasatoshiTamada, Koji
- [26] A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activityINTERNATIONAL IMMUNOPHARMACOLOGY, 2016, 31 : 248 - 256Luan, YanChai, DafeiPeng, JianjianMa, ShuliWang, MinMa, HuiLi, XiangFu, ShilongPan, XiaolongWang, XiaoxiaoQin, SongbingXu, Ting
- [27] A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockadeNature Communications, 12Cecile GeuijenPaul TackenLiang-Chuan WangRinse KloosterPieter Fokko van LooJing ZhouArpita MondalYao-bin LiuArjen KramerThomas CondamineAlla VolginaLinda J. A. HendriksHans van der MaadenEric RoversSteef EngelsFloris FransenRenate den Blanken-SmitVanessa Zondag-van der ZandeAbdul BasmelehWillem BartelinkAshwini KulkarniWilfred MarissenCheng-Yen HuangLeslie HallShane HarveySoyeon KimMarina MartinezShaun O’BrienEdmund MoonSteven AlbeldaChrysi KanellopoulouShaun StewartHoracio NastriAlexander B. H. BakkerPeggy ScherleTon LogtenbergGregory HollisJohn de KruifReid HuberPatrick A. MayesMark Throsby
- [28] FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 AxisCANCER CELL, 2015, 28 (03) : 285 - 295Dahan, RonySega, EmanuelaEngelhardt, JohnSelby, MarkKorman, Alan J.Ravetch, Jeffrey V.
- [29] Loss of RBMS1 promotes anti-tumor immunity through enabling PD-L1 checkpoint blockade in triple-negative breast cancerCell Death & Differentiation, 2022, 29 : 2247 - 2261Jinrui ZhangGe ZhangWenjing ZhangLu BaiLuning WangTiantian LiLi YanYang XuDan ChenWenting GaoChuanzhou GaoChaoqun ChenMenglin RenYuexia JiaoHongqiang QinYu SunLili ZhiYangfan QiJinyao ZhaoQuentin LiuHan LiuYang Wang
- [30] Loss of RBMS1 promotes anti-tumor immunity through enabling PD-L1 checkpoint blockade in triple-negative breast cancerCELL DEATH AND DIFFERENTIATION, 2022, 29 (11): : 2247 - 2261Zhang, JinruiZhang, GeZhang, WenjingBai, LuWang, LuningLi, TiantianYan, LiXu, YangChen, DanGao, WentingGao, ChuanzhouChen, ChaoqunRen, MenglinJiao, YuexiaQin, HongqiangSun, YuZhi, LiliQi, YangfanZhao, JinyaoLiu, QuentinLiu, HanWang, Yang